Drug Trial Radar · NCT04025541
Analysis of Circulating Tumor Markers in Blood
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
992
Planned (sponsor's estimate)
Start
May 29, 2018
Primary completion
May 29, 2029
Study completion May 29, 2032
Sponsor
- Lead sponsor
- Institut du Cancer de Montpellier - Val d'AurelleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 19, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
Conditions
- Cancer
- Breast Cancer
- Sarcoma
- Lung Cancers
- Glioma
- Colon Cancer
Interventions
Blood samplingBiological
blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time
Blood sampling C3Biological
Blood samples will be collected at four key time points: * baseline (T1), * first scan assessment (T2), * second scan assessment (T3), * and progression (T4).
Blood sampling C4/7/10/13Biological
Blood samples will be collected before any treatment
Blood sampling C5Biological
Blood samples will be collected at four key time points: * At the inclusion (T1) * Before the beginning of the treatment (cycle 1 day 1) (T2) * After the first cycle of T-DXd (cycle 2 day 1) (T3) * At progression or at the end of the follow-up (after 3 years) (T4)
Blood sampling C6Biological
Blood samples will be collected at three key time points: * At the inclusion (T1) * For patients starting treatment at the time of inclusion (T2): * Chemotherapy: 3 months after inclusion, * Concurrent chemoradiotherapy with Temozolomide: 4-6 weeks after completion of radiotherapy, * For patients starting treatment at the time of inclusion: at the time of tumor progression if occurring within one year of inclusion, or 12 months after inclusion in the absence of progression (T3).
Blood sampling C8Biological
Blood samples will be collected at five key time points: * At the inclusion * At follow-up visit 2 to 6, every 3 months
Blood sampling C9Biological
Blood samples will be collected at four key time points: * At the inclusion before the beginning of the treatment (Cycle 1 Day 1) * After the first cycle of the first chemo-immunotherapy sequence (Cycle 2 Day 1) * After the first cycle of the second chemotherapy sequence (Cycle 2b Day 1) * After the end of the whole neo-adjuvant chemo-immunotherapy protocol, before surgery
Blood sampling C11 + FFPEBiological
Blood samples will be collected at five key time points: * At the inclusion (T1) * At first clinical evaluation (T2): 4th week after start of treatment * At first scan evaluation (T3a): 8th week after start of treatment * At the Nth scan evaluation (T3b, c, ...) * At progression (T4) Tumor sampling : * At the inclusion * At tumor progression
Blood sampling C12Biological
Blood samples will be collected at several points : * Inclusion: at the time of suspected leptomeningeal metastases, prior to any specific treatment, * Every 4 weeks until meningeal progression, or for a maximum of 4 months, * Then every 3 months beyond 4 months until meningeal progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimation of the feasibility of the various blood tumoral biomarkers analysisTime frame: 4 YEARS
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France · Recruiting
ICM
Montpellier, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.